Therefore, RET genetic screening of patients with apparently sporadic MTC represents a major tool for the preclinical diagnosis and early treatment of unsuspected affected family members and allows the identification of a relevant percentage of hidden FMTC. This evidence concerns the gene RET and medullary thyroid gland carcinoma.